中裕新藥
1 known investors
TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
BiotechHealthtechMedical Devices
Founders & leadership
JC
Jimmy ChangCEO
Investors · 1
Frequently asked questions
- What does 中裕新藥 do?
- TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
- Who are 中裕新藥's investors?
- 中裕新藥's investors include YFY Biotech Management Company.